Navigation Links
Non-alcoholic steatohepataitis (NASH) Pipeline Analysis
Date:2/24/2017

NEW YORK, Feb. 23, 2017 /PRNewswire/ -- Non-alcoholic steatohepataitis (NASH) Pipeline Analysis" gives comprehensive insights on the various drugs being developed for the treatment of NASH. The report covers all the drugs that are in various phases of development (Discovery, Preclinical & Clinical). The pipeline focuses on novel pharmacologic drugs & regenerative medicines covering small molecules, antibodies, stem cell therapies, recombinant proteins and RNA-based therapeutics, but excludes symptom relief drugs, generic combinations and supplemental drugs. The report also covers some of the hot targets in research for NASH treatments and NASH related biomarkers.

Read the full report: http://www.reportlinker.com/p04719470-summary/view-report.html

This report enables Pharmaceutical/Biotech companies, Academic institutes, Individual researchers, Investors, Medical technology companies, Service providers and other associated stake holders to identify and analyze the available licensing/collaborative commercial opportunities in the Non-alcoholic steatohepataitis (NASH) drugs market. The report also provide strategic insights on some of the molecules that are yet to be launched in the next few years.

Some of the key sections covered in the report are given below:
Epidemiology
In this section, epidemiology of NASH is reviewed to understand potential significance and impact of the disease.

Global & US prevalence rates
Hot Targets, Mechanisms & Therapies
In this section, various NASH associated targets, mechanism and upcoming therapies are discussed. Also, covers novel targets in early research for NASH along with disease progression biomarkers associated with NASH (Inflammatory, apoptosis, fibrosis)

Market analysis
In market analysis section, global NASH drugs market is indicated along with the estimated Peak sales ($) of leading clinical stage drugs forecasted from 2019-2025.

Forecasting model for NASH market
NASH market dynamics
NASH Market and estimated Peak sales of 8 clinical candidates (OCA-Intercept, Aramchol-Galmed, GR-MD-02-Gilead, Cenicriviroc-Tobira, Simtuzumab-Gilead, Remo Biphasic-Avolynt, IVA 337-Inventiva Pharma, GFT505-Genfit)
NASH related deals analysis with financials (upfront, milestones and royalties)
Funding scenario in NASH market

Pipeline Analysis
Pipeline analysis was carried to get deeper insights on various treatment modalities in discovery, preclinical & development section, pipelines from major companies were identified and Potential targets were reported along with Mechanism of action, Current development status & nature of molecule. Pipeline analysis by developmental stage (Discovery to Clinical development)

Pipeline analysis by modalities
Monoclonal Antibodies pipeline analysis
RNA-therapeutics pipeline analysis
Recombinant protein pipeline analysis
Pipeline analysis by leading players & Target analysis
Drug analysis based on mechanism (Anti-Inflammatory, Anti-fibrotic & Metabolic)

Key Players Analysis
The key player's analysis section provides an in-depth understanding of various companies working on Nonalcoholic steatohepatitis (NASH) and their Pipelines with development phase as well as understanding partnering strategies such as deals entered by the company.
Global key players overview
Global key players Pipeline data (Discovery, Pre-clinical & Clinical development)
Global key players deals (Collaborations, Licensing, Service agreements, grants, funds)

Read the full report: http://www.reportlinker.com/p04719470-summary/view-report.html

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

http://www.reportlinker.com

__________________________
Contact Clare: clare@reportlinker.com
US: (339)-368-6001
Intl: +1 339-368-6001

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/non-alcoholic-steatohepataitis-nash-pipeline-analysis-300413100.html


'/>"/>
SOURCE Reportlinker
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. Tobira Therapeutics Doses First Patient in CENTAUR, A Phase 2b Study of Cenicriviroc in Patients with Non-Alcoholic Steatohepatitis
2. Arcturus Therapeutics Announces Collaboration with Takeda Pharmaceuticals to Develop RNA-based Therapeutics for the Treatment of Nonalcoholic Steatohepatitis (NASH)
3. New Emergence of Potential Tx & Dx Options Predicted to Transform the Current Landscape for Liver Diseases (NASH) to a $35 Billion Opportunity
4. Global Nonalcoholic Steatohepatitis (NASH) Market (Pipeline analysis, drug class, clinical trials and Geography) - Research Report, 2013 - 2020
5. Dermatology Therapeutics Drug Development Pipeline Review, 2016: Approximately One-Third of the US Population Suffers from at Least One Active Skin Condition - Research and Markets
6. Shire Reports Full Year 2016 Results With Record Revenue; Positioned for Continued Strong Growth Driven by Best-in-class Rare Disease Pipeline
7. Phylogica Ltd - Product Pipeline Review - 2016
8. Sumitomo Dainippon Pharma Co Ltd - Product Pipeline Review - 2016
9. Quark Pharmaceuticals Inc - Product Pipeline Review - 2016
10. Ornithine-Transcarbamylase Deficiency - Pipeline Review, H2 2016
11. Wilson Disease - Pipeline Review, H2 2016
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... received FDA 510(k) clearance in May 2017 for its highly anticipated ... for endoscopy environments. An innovative secondary monitor solution, ZeroWire Mobile ... the improvement of patient outcomes, procedural efficiency, and the lowering of ... ... By ...
(Date:10/5/2017)... , Oct. 5, 2017  In response to ... Oral and Maxillofacial Surgeons (AAOMS) released prescribing recommendations ... to be used as a first-line therapy to ... Recognizing the value ... White Paper "Opioid Prescribing: Acute and Postoperative Pain ...
(Date:10/4/2017)... Oct. 4, 2017 OBP Medical ... illuminating medical devices, today announced regulatory approval from ... Agency (or Agência Nacional de Vigilância Sanitária (ANVISA)) ... cordless surgical retractor with integrated LED light source ... illumination and exposure of a tissue pocket or ...
Breaking Medicine Technology:
(Date:10/13/2017)... , ... October 13, 2017 , ... Global Healthcare Management’s ... Alexandria Park in Milford, NJ. This free event, sponsored by Global Healthcare Management’s ... The fun run is geared towards children of all ages; it is a ...
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, a leader in ... awarded a contract by the Center for Medicare and Medicaid Services (CMS). The ... enterprise use of Agile methodologies in a consistent and high value manner across ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... services for healthcare compliance program management, will showcase a range of technology and ... for Assisted Living (NCAL) Convention and Expo to be held October 14–18, 2017 ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company ... of today’s consumer and regulatory authorities worldwide. From Children’s to Adults 50+, every ... meet the highest standard. , These products are also: Gluten Free, Non-GMO, ...
(Date:10/12/2017)... ... , ... Asante, a nationally recognized health system in southern ... home health joint venture through an agreement, effective October 1, 2017, to create ... health company with Asante, delivering clinically integrated care, for the past eight years. ...
Breaking Medicine News(10 mins):